How Does Glanzmann Thrombasthenia Differ From Hemophilia
At a Glance
Glanzmann Thrombasthenia affects blood platelets (the 'bricks' of a clot), whereas Hemophilia affects clotting factors (the 'mortar'). This fundamental difference means the two disorders cause distinct bleeding patterns and require completely different medical treatments.
Because Hemophilia is the most well-known bleeding disorder, you may find that friends, family, or even non-specialist doctors use it as a reference point. While both Glanzmann Thrombasthenia (GT) and Hemophilia are rare bleeding disorders, they affect completely different parts of the blood-clotting process [1]. Understanding the specific differences helps clarify your exact diagnosis and ensures you receive the correct care.
The “Bricks and Mortar” Analogy
To understand the difference, it helps to think of a blood clot like a brick wall. In this analogy, blood platelets are the “bricks,” and clotting factors in the blood plasma are the “mortar” that holds them together.
Hemophilia is a disorder caused by missing “mortar” (specifically, clotting factors VIII or IX) [2]. Glanzmann Thrombasthenia, however, is a disorder of the “bricks” (the platelets) [3]. Specifically, in GT, the platelets are missing the “hooks” (a protein complex called GPIIb/IIIa) needed to grab onto each other and form a strong, stable plug [4][2].
Differences in Bleeding Patterns
Because GT and Hemophilia disrupt different stages of clotting, they cause distinct patterns of bleeding [5].
Glanzmann Thrombasthenia primarily causes mucocutaneous bleeding, which means it affects the mucous membranes and skin [5][6]. This typically looks like severe nosebleeds, bleeding gums, easy bruising, and heavy menstrual periods [7].
Hemophilia, on the other hand, is known for deep tissue bleeding [5]. People with Hemophilia are more likely to experience bleeding deep within their muscles and joints (hemarthrosis), which causes pain, swelling, and long-term joint damage [5][7]. While joint bleeds are a hallmark of Hemophilia, they are rare in platelet disorders like GT [6].
Differences in Treatment
Because the underlying problems are different, the treatments also differ significantly.
Hemophilia is typically managed with factor replacement therapy (infusing the missing “mortar” directly into the blood) or newer non-factor medications like emicizumab to prevent or treat bleeds [8].
For Glanzmann Thrombasthenia, treatment focuses on managing immediate bleeding. Your care team might use specific medications called antifibrinolytics (like tranexamic acid), platelet transfusions, or a special clotting drug called recombinant activated factor VII (rFVIIa) [9][10]. Strategies that work for Hemophilia will not fix the missing platelet “hooks” in GT, which is why having an accurate diagnosis and an individualized treatment plan is so critical [11][12].
At a Glance: GT vs. Hemophilia
| Feature | Glanzmann Thrombasthenia (GT) | Hemophilia |
|---|---|---|
| Defect Type | Platelets (The “Bricks”) | Clotting Factors (The “Mortar”) |
| Specific Issue | Missing platelet “hooks” (GPIIb/IIIa) | Missing clotting factors (VIII or IX) |
| Bleeding Pattern | Mucous membranes and skin (nose, gums, heavy periods) | Deep tissue and joints |
| Typical Treatments | Antifibrinolytics, platelet transfusions, rFVIIa | Factor replacement therapy, non-factor therapies |
Common questions in this guide
What is the main difference between Glanzmann Thrombasthenia and Hemophilia?
Are the bleeding symptoms different for GT compared to Hemophilia?
Can Hemophilia treatments be used for Glanzmann Thrombasthenia?
How can I explain Glanzmann Thrombasthenia using the bricks and mortar analogy?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Bleeding patterns
What differences in bleeding patterns would you look for to tell GT from hemophilia?
Treatment options
What treatment options would be used to manage bleeding in GT?
Why treatments differ
Why would hemophilia treatments not work for GT, and what would be used instead?
Related questions
Get notified when new evidence is published on Glanzmann Thrombasthenia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (12)
- 1
Anti-platelet treatment challenges in Glanzmann thrombasthenia-clinical practice when data lacks.
Scafa-Udriște A, Popa-Fotea NM, Calmac L, et al.
Haemophilia : the official journal of the World Federation of Hemophilia 2022; (28(4)):e98-e100 doi:10.1111/hae.14527.
PMID: 35218677 - 2
Novel mutations in Thai patients with glanzmann thrombasthenia.
Ittiwut R, Suchartlikitwong P, Kittikalayawong Y, et al.
European journal of haematology 2017; (99(6)):520-524 doi:10.1111/ejh.12965.
PMID: 28888044 - 3
Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy.
Nurden P, Stritt S, Favier R, Nurden AT
Haematologica 2021; (106(2)):337-350 doi:10.3324/haematol.2020.248153.
PMID: 33147934 - 4
Two homozygous missense mutations in ITGB3 gene as a cause of Glanzmann Thrombasthenia in four consanguineous Pakistani pedigrees.
Ali T, Gul S, Amar A, et al.
International journal of laboratory hematology 2020; (42(5)):628-635 doi:10.1111/ijlh.13266.
PMID: 32558238 - 5
Glanzmann Thrombasthenia Associated with Siderotic Synovitis and Arthropathy: A Case Report.
Alawad MJ, Abu-Tineh M, Alshurafa A, et al.
Journal of blood medicine 2023; (14()):563-567 doi:10.2147/JBM.S418937.
PMID: 37941894 - 6
Apixaban for treatment of venous thromboembolism in an obese patient with Glanzmann thrombasthenia.
Sattler L, Wimmer J, Herb A, et al.
Research and practice in thrombosis and haemostasis 2023; (7(4)):100183 doi:10.1016/j.rpth.2023.100183.
PMID: 37538495 - 7
Obstetric and Gynaecological Challenges and Outcomes in Women and Girls With Glanzmann's Thrombasthenia.
Obeng-Tuudah D, Tarawah A, Ozkan M, Abdul-Kadir R
Haemophilia : the official journal of the World Federation of Hemophilia 2025; (31(3)):509-518 doi:10.1111/hae.70030.
PMID: 40123272 - 8
How we treat the platelet glycoprotein defects; Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults.
Grainger JD, Thachil J, Will AM
British journal of haematology 2018; (182(5)):621-632 doi:10.1111/bjh.15409.
PMID: 30117143 - 9
Two case reports of Glanzmann thrombasthenia with intracranial hemorrhage and a review of the literature.
Almesedin GS, Alshmaily HO, Alshammari KA, Albalawi RS
Surgical neurology international 2023; (14()):448 doi:10.25259/SNI_680_2023.
PMID: 38213436 - 10
The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention.
Poon MC, d'Oiron R, Zotz RB, et al.
Haematologica 2015; (100(8)):1038-44 doi:10.3324/haematol.2014.121384.
PMID: 26001792 - 11
Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review.
Saultier P, Grino M, Falaise C, et al.
Haemophilia : the official journal of the World Federation of Hemophilia 2025; (31(1)):7-15 doi:10.1111/hae.15130.
PMID: 39604156 - 12
The Use of Recombinant Activated Factor VII in Patients with Glanzmann's Thrombasthenia.
Poon MC
Thrombosis and haemostasis 2021; (121(3)):332-340 doi:10.1055/s-0040-1718373.
PMID: 33124022
This page compares rare bleeding disorders for educational purposes only. Always consult your hematologist for an accurate diagnosis and an individualized treatment plan.